为提高自有资金使用效率，在确保不影响正常经营和资金安全的情况下，公 司拟使用暂时闲置的自有资金进行现金管理，以更好的实现公司现金的保值增值， 保障公司股东的利益。 证券代码：301201 证券简称：诚达药业 公告编号：2025-051 诚达药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2025 年 11 月 19 日召开公 司第六届董事会第二次会议，审议通过了《关于使用闲置自有资金进行现金管理 的议案》并同意将此议案提交股东会审议。为提高闲置自有资金的使用效率，增 加公司资金收益，在不影响公司正常经营及确保资金安全的情况下，同意公司及 子公司使用不超过人民币 7 亿元（含本数）的闲置自有资金进行现金管理，用于 购买风险较低、流动性好、期限不超过 12 个月的产品（包括但不限于协定存款、 通知存款、定期存款、结构性存款、购买金融机构理财产品等）。使用期限自公 司股东会审议通过之日起不超过 12 个月。在上述额度和期限范围内，资金可循 环滚动使用。本议案尚需提交 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-052 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： 诚达药业股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 （1）现场会议时间：2025 年 12 月 5 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 5 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票 的具体时间为 2025 年 12 月 5 日 9:15 至 15:00 的任意时间。 7、出席对象： （1）在股权登记日持有公司已发行有表决权股份的股东或其代理人； 截至 2 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-049 二、董事会会议审议情况 会议经全体董事讨论后形成如下决议： （一）审议通过《关于使用闲置募集资金进行现金管理的议案》 为充分利用公司闲置募集资金，提高资金利用效率，增加资金收益，同意公 司在确保不影响募集资金投资计划正常进行和募集资金安全的前提下，拟使用不 超过人民币 8 亿元（含本数）的闲置募集资金（含超募资金）进行现金管理，用 于购买安全性高、流动性好、期限不超过 12 个月的产品（包括但不限于协定存 款、通知存款、定期存款、结构性存款等现金管理类产品）。使用期限自公司股 东会审议通过之日起不超过 12 个月。在上述额度和期限范围内，资金可循环滚 动使用。同时公司董事会提请股东会授权公司经营管理层在上述额度内行使该项 决策权并签署相关协议及办理相关具体事宜。 诚达药业股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 诚达药业股份有限公司（以下简称"公司"）第六届董事会第二次会议于 2025 年 11 月 19 日在公司 ...

Core Viewpoint - Chengda Pharmaceutical experienced a significant increase in stock price, reaching a daily limit of 20% with a trading volume of 1.45 billion yuan and a turnover rate of 23.07% [2] Trading Activity - The stock's trading activity included a total turnover of 5.46 billion yuan among the top five trading departments, with a net buying amount of 396.83 million yuan [2] - Institutional investors net sold 10.52 million yuan, while the total net buying from brokerage seats amounted to 50.20 million yuan [2] Fund Flow - The stock saw a net inflow of 95.37 million yuan from major funds, with large orders contributing a net inflow of 97.14 million yuan, while smaller orders experienced a net outflow of 1.77 million yuan [2] - Over the past five days, the net inflow of major funds reached 95.84 million yuan [2] Institutional Participation - Five institutional specialized seats were involved in trading, with total buying amounting to 188 million yuan and selling amounting to 198 million yuan, resulting in a net sell of 10.52 million yuan [2] - Specific trading details showed that the top buying department was Guotai Junan Securities in Shanghai, with a buying amount of 524.15 million yuan and a selling amount of 1.42 million yuan [2]

Market Overview - As of November 18, the Shanghai Composite Index closed at 3939.81 points, down 32.22 points, a decline of 0.81% [1] - The Shenzhen Component Index closed at 13080.49 points, down 121.52 points, a decline of 0.92% [1] - The ChiNext Index closed at 3069.22 points, down 35.98 points, a decline of 1.16% [1] High Turnover Stocks - A total of 100 A-shares had a turnover rate exceeding 20% on November 18, with six stocks, including Beikong Detection and C Hengkong, having turnover rates above 50% [1] - Beikong Detection (stock code: 920160) had a closing price of 26.50 yuan and a turnover rate of 88.46%, with a price increase of 295.52% [1] - C Hengkong (stock code: 688727) closed at 61.55 yuan, with a turnover rate of 81.36% and a price increase of 310.61% [1] - Other notable stocks with high turnover rates include C Nanshu (75.35% turnover, 224.78% increase) and Zhongfutong (53.96% turnover, -3.19% decrease) [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - Xue Ren Group (50.33% turnover, -2.55% decrease) [1] - Jianglong Boat (46.42% turnover, -2.02% decrease) [1] - Xuanya International (44.73% turnover, 20.01% increase) [1] - Hongxiang Co. (44.63% turnover, 5.98% increase) [1] - The list continues with various companies showing diverse performance in terms of turnover and price changes [2][3][4]

Group 1: Stem Cell Projects - The company is developing stem cell projects for treating heart failure after myocardial infarction and sequelae after cerebral infarction, such as paralysis and speech disorders [2][3] - The stem cells used are mesenchymal stem cells sourced from umbilical cords, which have good in vitro expansion capabilities and maintain their tri-lineage differentiation potential [2][3] - The company has established a technical collaboration with Chiron Pharma, Inc. for the implementation of these projects in mainland China, Hong Kong, and Macau [2][3] Group 2: Project Progress and Infrastructure - The company has completed the design, installation, and validation of GMP facilities for the stem cell projects, including the establishment of seed, master, and working cell banks [3] - The company is preparing for IND submission by completing process validation and developing analytical methods [3] Group 3: Future Business Directions - A wholly-owned subsidiary, Shanghai Jiuqian Cheng Biomedical Co., Ltd., has been established to advance stem cell projects, with future business directions to be determined based on market demand [3] - In addition to stem cell projects, the company continues to focus on its core business of providing key pharmaceutical intermediates and CDMO services, with a recent investment of 70 million yuan in Chengdu Shibeikang Biomedical Technology Co., Ltd. for innovative drug collaboration [3] Group 4: Business Operations - The company's CDMO services include small molecule drug intermediates, small nucleic acid drug intermediates, and raw materials for innovative drugs [3] - The company is committed to disclosing any significant information in accordance with regulations [3]

Core Insights - The medical services sector experienced a decline of 0.76% on November 18, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Medical Services Sector Performance - Chengda Pharmaceutical saw a significant increase of 20.01%, closing at 59.50, with a trading volume of 250,400 shares and a transaction value of 1.45 billion [1] - Other notable gainers included Digital Human (+4.49%), Dian Diagnostics (+3.84%), and Meinian Health (+3.25%) [1] - Conversely, Zihua Pharmaceutical led the declines with a drop of 4.39%, closing at 10.23, followed by Innovative Medical (-3.86%) and Tigermed (-3.42%) [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 1.348 billion from institutional investors, while retail investors saw a net inflow of 1.001 billion [2][3] - Notable stocks with significant capital inflows included Meinian Health with a net inflow of 1.39 billion, while Chengda Pharmaceutical had a net inflow of 931.01 million [3] - The overall trend indicates a shift in investor sentiment, with retail investors actively participating despite institutional outflows [2][3]

Investment Rating - The report does not explicitly state an investment rating for the industry [2][19]. Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 3.29%, outperforming the Wind All A index (-0.47%) and the CSI 300 index (-1.08%) during the week of November 10-14, 2025 [3][8]. - Local governments are actively implementing policies to support innovative drug development, with Chongqing aiming to approve 1-3 new drugs annually by 2027 [3][13]. - Flu activity is on the rise, with the percentage of flu-like illness cases reported in southern provinces reaching 5.5%, higher than the previous week and the same period in 2022 and 2024 [3][13]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 3.29%, with all sub-sectors recovering. The leading sub-sectors included pharmaceutical distribution (5.92%), in vitro diagnostics (5.91%), and raw materials (5.09%) [3][8]. - Notable stock performances included Jindike (61.6%), Renmin Tongtai (61.1%), and Chengda Pharmaceutical (58.3%) with significant gains, while *ST Changyao (-33.6%) and Zhend Medical (-11.3%) faced substantial declines [3][11]. Industry News and Key Company Announcements - On November 14, Chongqing's government announced comprehensive support measures for innovative drug development, including funding for research and expedited ethical review processes [3][13]. - Merck announced a $9.2 billion acquisition of Cidara Therapeutics, expected to close in Q1 2026 [3][13]. - Adicon acquired Crown Bioscience for $204 million, aiming to enhance its integrated service platform [3][13]. - Laika Pharmaceuticals entered an exclusive licensing agreement with Qilu Pharmaceutical for LAE002, with potential payments totaling RMB 25.75 billion [3][14]. - Lyell Immunopharma announced a global licensing agreement for LYL273, with significant milestone payments and royalties [3][15]. - MeiraGTx Holdings entered a strategic collaboration with Eli Lilly for gene therapy projects, with upfront and milestone payments exceeding $400 million [3][15].

Core Insights - Chengda Pharmaceutical experienced a trading halt with a daily price increase of 20.00%, leading to a turnover rate of 21.73% and a transaction volume of 1.087 billion yuan [2] - Institutional investors net bought 33.577 million yuan, while brokerage seats collectively net sold 84.8621 million yuan [2] Trading Activity - The stock was listed on the Shenzhen Stock Exchange due to its closing price increase of 20.00% [2] - The top five trading departments accounted for a total transaction volume of 416 million yuan, with a buying amount of 182 million yuan and a selling amount of 234 million yuan, resulting in a net sell of 51.2851 million yuan [2] - Among the trading departments, five institutional special seats were involved, with a total buying amount of 136 million yuan and a selling amount of 103 million yuan, leading to a net buy of 33.577 million yuan [2] Fund Flow - The stock saw a net inflow of 36.1728 million yuan from major funds, with a significant single order net inflow of 125 million yuan, while large orders experienced a net outflow of 88.5771 million yuan [2] - Over the past five days, the net outflow of major funds amounted to 3.8427 million yuan [2]

Core Viewpoint - The stock of Chengda Pharmaceutical experienced an abnormal trading fluctuation, with a cumulative price increase of over 30% over two consecutive trading days, prompting an inquiry by the Shenzhen Stock Exchange [1] Summary by Relevant Sections - **Stock Price Movement** - Chengda Pharmaceutical's stock price increased by over 30% from November 13 to November 14, 2025, indicating significant trading volatility [1] - **Company Confirmation** - The company's board confirmed that there are no corrections or supplements needed for previously disclosed information, and there are no undisclosed significant matters that could impact the stock price [1] - **Market Environment** - The company stated that its operational situation remains normal, with no significant changes in the internal or external environment [1] - **Insider Trading** - The controlling shareholders and actual controllers did not engage in buying or selling the company's stock during the period of abnormal price fluctuation [1] - **Disclosure Compliance** - The company affirmed that it has not violated any fair information disclosure regulations and that there are no undisclosed matters that could significantly affect the stock price [1]